dc.contributor.author | Creagh, Emma | en |
dc.contributor.author | O'Sullivan, Jacintha | en |
dc.contributor.author | Reynolds, John | en |
dc.contributor.author | Ravi, Narayanasamy | en |
dc.contributor.author | Phelan, James | en |
dc.date.accessioned | 2020-10-19T12:23:16Z | |
dc.date.available | 2020-10-19T12:23:16Z | |
dc.date.issued | 2020 | en |
dc.date.submitted | 2020 | en |
dc.identifier.citation | G. Barber, A. Anand, K. Oficjalska, J.J. Phelan, A. B. Heeran, E. Flis, N. E. Clarke, J. A. Watson, J. Strangmann, B. Flood, H. O�Neill, D. O�Toole, F. MacCarthy, N. Ravi, J. V. Reynolds, E.W. Kay, M. Quante, J. O�Sullivan, E.M. Creagh., Characterizing caspase-1 involvement during esophageal disease progression., Cancer Immunology Immunotherapy, 69, 12, 2020, 2635 - 2649 | en |
dc.identifier.issn | 0340-7004 | en |
dc.identifier.other | Y | en |
dc.description | PUBLISHED | en |
dc.description.abstract | Barrett’s esophagus (BE) is an inflammatory condition and a neoplastic precursor to esophageal adenocarcinoma (EAC). Inflammasome signaling, which contributes to acute and chronic inflammation, results in caspase-1 activation leading to the secretion of IL-1β and IL-18, and inflammatory cell death (pyroptosis). This study aimed to characterize caspase-1 expression, and its functional importance, during disease progression to BE and EAC. Three models of disease progression (Normal–BE–EAC) were employed to profile caspase-1 expression: (1) a human esophageal cell line model; (2) a murine model of BE; and (3) resected tissue from BE-associated EAC patients. BE patient biopsies and murine BE organoids were cultured ex vivo in the presence of a caspase-1 inhibitor, to determine the importance of caspase-1 for inflammatory cytokine and chemokine secretion.
Epithelial caspase-1 expression levels were significantly enhanced in BE (p < 0.01). In contrast, stromal caspase-1 levels correlated with histological inflammation scores during disease progression (p < 0.05). Elevated secretion of IL-1β from BE explanted tissue, compared to adjacent normal tissue (p < 0.01), confirmed enhanced activity of caspase-1 in BE tissue. Caspase-1 inhibition in LPS-stimulated murine BE organoids caused a significant reduction in IL-1β (p < 0.01) and CXCL1 (p < 0.05) secretion, confirming the importance of caspase-1 in the production of cytokines and chemokines associated with disease progression from BE to EAC. Targeting caspase-1 activity in BE patients should therefore be tested as a novel strategy to prevent inflammatory complications associated with disease progression. | en |
dc.format.extent | 2635 | en |
dc.format.extent | 2649 | en |
dc.language.iso | en | en |
dc.relation.ispartofseries | Cancer Immunology Immunotherapy | en |
dc.relation.ispartofseries | 69 | en |
dc.relation.ispartofseries | 12 | en |
dc.rights | Y | en |
dc.subject | Esophageal cancer | en |
dc.subject | Inflammation | en |
dc.subject | Barrett’s metaplasia | en |
dc.subject | Inflammasome | en |
dc.title | Characterizing caspase-1 involvement during esophageal disease progression. | en |
dc.type | Journal Article | en |
dc.type.supercollection | scholarly_publications | en |
dc.type.supercollection | refereed_publications | en |
dc.identifier.peoplefinderurl | http://people.tcd.ie/ecreagh | en |
dc.identifier.peoplefinderurl | http://people.tcd.ie/reynoljv | en |
dc.identifier.peoplefinderurl | http://people.tcd.ie/phelanj3 | en |
dc.identifier.peoplefinderurl | http://people.tcd.ie/osullij4 | en |
dc.identifier.peoplefinderurl | http://people.tcd.ie/ravin | en |
dc.identifier.rssinternalid | 217058 | en |
dc.identifier.doi | http://dx.doi.org/10.1007/s00262-020-02650-4 | en |
dc.rights.ecaccessrights | openAccess | |
dc.subject.TCDTheme | Cancer | en |
dc.subject.TCDTheme | Immunology, Inflammation & Infection | en |
dc.subject.TCDTag | BARRETTS ESOPHAGUS | en |
dc.subject.TCDTag | Inflammasome-mediated inflammation | en |
dc.subject.TCDTag | Oesophageal Cancer | en |
dc.subject.TCDTag | caspase-1 | en |
dc.identifier.orcid_id | 0000-0001-7631-4370 | en |
dc.subject.darat_impairment | Chronic Health Condition | en |
dc.subject.darat_thematic | Health | en |
dc.status.accessible | N | en |
dc.contributor.sponsor | European Union (EU) | en |
dc.contributor.sponsorGrantNumber | 721906 | en |
dc.contributor.sponsor | TCD | en |
dc.identifier.uri | http://hdl.handle.net/2262/93838 | |